These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28558376)

  • 1. Long-Term Outcomes of Patients with Central Precocious Puberty due to Hypothalamic Hamartoma after GnRHa Treatment: Anthropometric, Metabolic, and Reproductive Aspects.
    Ramos CO; Latronico AC; Cukier P; Macedo DB; Bessa DS; Cunha-Silva M; Arnhold IJ; Mendonca BB; Brito VN
    Neuroendocrinology; 2018; 106(3):203-210. PubMed ID: 28558376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of gonadotropin-releasing analog treatment for children with central precocious puberty: 15-year experience in southern Thailand.
    Jaruratanasirikul S; Thaiwong M
    J Pediatr Endocrinol Metab; 2011; 24(7-8):519-23. PubMed ID: 21932591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy.
    Feuillan PP; Jones JV; Barnes KM; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4036-8. PubMed ID: 11095429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Patients with Central Precocious Puberty Due to Loss-of-Function Mutations in the MKRN3 Gene after Treatment with Gonadotropin-Releasing Hormone Analog.
    Ramos CO; Macedo DB; Canton APM; Cunha-Silva M; Antonini SRR; Stecchini MF; Seraphim CE; Rodrigues T; Mendonca BB; Latronico AC; Brito VN
    Neuroendocrinology; 2020; 110(7-8):705-713. PubMed ID: 31671431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg).
    Ramos CO; Canton APM; Seraphim CE; Faria AG; Tinano FR; Mendonca BB; Latronico AC; Brito VN
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1371-1377. PubMed ID: 34298591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot.
    de Brito VN; Latronico AC; Arnhold IJ; Lo LS; Domenice S; Albano MC; Fragoso MC; Mendonca BB
    Arch Dis Child; 1999 Mar; 80(3):231-4. PubMed ID: 10325702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothalamic hamartoma: comparison of clinical presentation and magnetic resonance images.
    Debeneix C; Bourgeois M; Trivin C; Sainte-Rose C; Brauner R
    Horm Res; 2001; 56(1-2):12-8. PubMed ID: 11815722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical treatment of hypothalamic hamartoma causing central precocious puberty: long-term follow-up.
    Li CD; Luo SQ; Gong J; Ma ZY; Jia G; Zhang YQ; Li JF
    J Neurosurg Pediatr; 2013 Aug; 12(2):151-4. PubMed ID: 23746126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
    Poomthavorn P; Suphasit R; Mahachoklertwattana P
    Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
    Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
    Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
    Palmert MR; Mansfield MJ; Crowley WF; Crigler JF; Crawford JD; Boepple PA
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4480-8. PubMed ID: 10599706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
    Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of gonadotropin-releasing hormone analogs on body mass index in girls with idiopathic central precocious puberty: a long-term follow-up study].
    Yuan JN; Liang L; Cai XD; Li Z; Bai M; Gu CP
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Nov; 13(11):896-9. PubMed ID: 22099200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results.
    Mul D; Bertelloni S; Carel JC; Saggese G; Chaussain JL; Oostdijk W
    Horm Res; 2002; 58(1):1-7. PubMed ID: 12169774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final adult height in children with central precocious puberty - a retrospective study.
    Knific T; Lazarevič M; Žibert J; Obolnar N; Aleksovska N; Šuput Omladič J; Battelino T; Avbelj Stefanija M
    Front Endocrinol (Lausanne); 2022; 13():1008474. PubMed ID: 36531464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty.
    Rizzo V; De Sanctis V; Corrias A; Fortini M; Galluzzi F; Bertelloni S; Guarneri MP; Pozzan G; Cisternino M; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():781-6. PubMed ID: 10969921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near final adult height, and body mass index in overweight/obese and normal-weight children with idiopathic central precocious puberty and treated with gonadotropin-releasing hormone analogs.
    Sinthuprasith P; Dejkhamron P; Wejaphikul K; Unachak K
    J Pediatr Endocrinol Metab; 2019 Dec; 32(12):1369-1375. PubMed ID: 31605579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
    Antoniazzi F; Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Borrelli P; Osio D; Mengarda F; De Luca F; Tatò L
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.